Viridian Therapeutics, Inc.\DE (VRDN) Change in Accured Expenses (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Change in Accured Expenses of -$23.7 million for Q1 2026, down 48.92% year-over-year from -$46.4 million in Q1 2025, and down 211.12% quarter-over-quarter from $21.3 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Change in Accured Expenses history runs 14 years deep, the most recent figure standing at -$23.7 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 48.92% year-over-year to -$23.7 million; the TTM figure through Mar 2026 stood at $8.4 million (up 33.2% YoY), while the FY2025 annual figure was $16.2 million, down 24.04% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$23.7 million, down from $21.3 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $21.3 million in Q4 2025, with the low at -$23.7 million in Q1 2026.
- The 5-year median for Change in Accured Expenses is $3.9 million (2024), against an average of $1.5 million.
- The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses surged 433.33% in 2023, then sank 1679.08% in 2025.
- Viridian Therapeutics, Inc.\DE's Change in Accured Expenses stood at $6.0 million in 2022, then slipped by 24.48% to $4.5 million in 2023, then surged by 138.05% to $10.8 million in 2024, then surged by 97.5% to $21.3 million in 2025, then sank by 211.12% to -$23.7 million in 2026.
- Business Quant data shows VRDN's Change in Accured Expenses at -$23.7 million in Q1 2026, $21.3 million in Q4 2025, and $4.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 6.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.11 Mn |
| Jun 30, 2026 | 6.11 Mn |
| Mar 31, 2026 | -23.69 Mn |
| Mar 31, 2026 | -23.69 Mn |
| Dec 31, 2025 | 21.32 Mn |
| Dec 31, 2025 | 21.32 Mn |
| Sep 30, 2025 | 4.61 Mn |
| Sep 30, 2025 | 4.61 Mn |
| Jun 30, 2025 | 6.18 Mn |
| Jun 30, 2025 | 6.18 Mn |
| Mar 31, 2025 | -15.91 Mn |
| Mar 31, 2025 | -15.91 Mn |
| Dec 31, 2024 | 10.79 Mn |
| Dec 31, 2024 | 10.79 Mn |
| Sep 30, 2024 | 3.91 Mn |
| Sep 30, 2024 | 3.91 Mn |
| Jun 30, 2024 | 7.53 Mn |
| Jun 30, 2024 | 7.53 Mn |
| Mar 31, 2024 | -894,000.00 |
| Mar 31, 2024 | -894,000.00 |